Cambrex (CBM) Downgraded by Longbow Research

Cambrex (NYSE:CBM) was downgraded by equities researchers at Longbow Research from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports.

Several other research firms have also recently commented on CBM. William Blair began coverage on Cambrex in a research note on Tuesday, January 16th. They set an “outperform” rating for the company. Zacks Investment Research upgraded Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday, January 15th. Finally, Craig Hallum restated a “buy” rating and set a $60.00 price target (down previously from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. Cambrex has an average rating of “Hold” and an average target price of $60.00.

Cambrex (NYSE:CBM) traded down $1.45 during mid-day trading on Wednesday, hitting $53.50. The stock had a trading volume of 522,544 shares, compared to its average volume of 393,495. The firm has a market capitalization of $1,747.45, a P/E ratio of 17.43, a P/E/G ratio of 1.24 and a beta of 2.38. Cambrex has a 1-year low of $42.55 and a 1-year high of $62.95.

Cambrex (NYSE:CBM) last posted its quarterly earnings data on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.10 by $0.17. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The business had revenue of $182.28 million during the quarter, compared to the consensus estimate of $181.39 million. During the same period in the prior year, the company earned $1.23 earnings per share. The company’s revenue was up 2.5% compared to the same quarter last year. equities analysts anticipate that Cambrex will post 2.85 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Advisor Group Inc. raised its stake in shares of Cambrex by 29.8% during the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 615 shares during the last quarter. Financial Gravity Companies Inc. purchased a new stake in shares of Cambrex during the fourth quarter worth approximately $166,000. Visionary Asset Management Inc. purchased a new stake in shares of Cambrex during the third quarter worth approximately $201,000. MML Investors Services LLC purchased a new stake in shares of Cambrex during the fourth quarter worth approximately $204,000. Finally, Two Sigma Securities LLC purchased a new stake in shares of Cambrex during the fourth quarter worth approximately $207,000.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/14/cambrex-cbm-downgraded-by-longbow-research.html.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply